GlobeNewswire EN Nachrichten

 

Woodward, Inc. (NASDAQ: WWD) and Lufthansa Technik have entered an Elite Licensed Repair Service Facility Agreement (LRSF)....

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common stock at a purchase price of $23.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Maze from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Maze, are expected to be $150 million. The offering is expected to close on or about April 23, 2026, subject to the satisfaction of customary closing conditions. All of the securities are being offered by Maze....

SHENZHEN, China, April 21, 2026 (GLOBE NEWSWIRE) -- On April 17th, Han's Laser (002008.SZ) released its 2025 annual report. The report indicates that Han's Laser exceeded annual revenue of USD 2.67 billion, up 27.00% year-on-year, marking a three-year high in revenue scale. Its net profit attributable to shareholders of the listed company was CNY 1.19 billion, while its net profit attributable to shareholders of the listed company excluding non-recurring gains and losses was CNY 810 million, with the latter surging by as much as 82.28% year-on-year, reflecting continuous improvement in its operating quality. Driven by the three major trends of explosive growth in AI computing power, the globalization of new energy, and the domestic substitution of semiconductors, Han's Laser leverages its vertically integrated technological advantages to further deepen its presence in the intelligent manufacturing equipment sector. With a continuously optimized business portfolio and robust core growth drivers, it ha...

NATIONAL HARBOR, Md., April 21, 2026 (GLOBE NEWSWIRE) -- At the U.S. Navy League's Sea-Air-Space Exposition 2026 today, Kari Wilkinson, HII (NYSE: HII) executive vice president and president of Newport News Shipbuilding, highlighted the company's commitment to strengthen and expand the U.S. maritime industrial base....

MEXICO CITY, April 21, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroméxico S.A.B. de C.V. (NYSE: AERO & BMV: AERO) (“Aeroméxico”) will hold a live conference call and webcast on Wednesday, April 22, 2026, at 10:30 a.m. Mexico City Time (12:30 p.m. Eastern Time / NY Time) to discuss its first quarter 2026 financial results....

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Figure Technology Solutions (Nasdaq: FIGR; OPEN: FGRS), the leading blockchain-native capital marketplace for the origination, funding, sale, and trading of tokenized assets, today announced that it plans to report its First Quarter 2026 results on Monday, May 11, 2026, after market close. The company will host a conference call to discuss the results, outlook, and related matters the following morning, Tuesday, May 12, 2026, at 8:30 a.m. Eastern Time....

ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from clinical studies of three key drug candidates have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in person at McCormick Place in Chicago, IL, and online, May 29 – June 2, 2026. With three abstracts selected for rapid oral presentations and three abstracts selected for poster presentations, these data highlight the global innovation and clinical value of Ascentage Pharma's portfolio, inclusive of Olverembatinib (HQP1351), the first third-generation BCR-ABL inhibitor approved in China; Lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibi...

PERTH, Australia, April 21, 2026 (GLOBE NEWSWIRE) -- Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (“Paladin” or the “Company”) is pleased to advise that it has released its quarterly report for the three month period ended 31 March 2026 (“March 2026 Quarter Results”)....

Basel, 22 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the positive Phase III FENhance 1 and 2 studies, which met their primary endpoint. The studies showed that fenebrutinib, an investigational non-covalent Bruton's tyrosine kinase (BTK) inhibitor, reduced the annualised relapse rate (ARR) by 51.1% (p...

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS...

CALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) -- Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) plans to release its financial results and operating highlights for the three months ended March 31, 2026, on Thursday, May 7, 2026 prior to market open. Results will be communicated by news release and will be available on the Company's website at www.enerflex.com and under the electronic profile of the Company on SEDAR+ and EDGAR at www.sedarplus.ca and www.sec.gov/edgar, respectively....

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (“Emerita” or the “Company”) (TSXV: EMO) (OTCQX: EMOTF) (FSE: LLJA) has become aware of a press release dated April 21, 2026 issued by Denarius Metals Corp. (“Denarius”) pursuant to which Denarius has indicated its intention to make an increased offer to acquire all of the issued and outstanding common shares of Emerita (the “Shares”). Please see the Company's press release dated April 13, 2026 for further details regarding the initial offer received from Denarius (the “Initial Offer”). Emerita has not received an additional written offer from Denarius following the receipt of the Initial Offer....

Shoals Technologies Group, Inc. Announces Participation in Upcoming Events for the Investor Community...

MEXICO CITY, April 21, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroméxico S.A.B. de C.V. (NYSE: AERO & BMV: AERO, “Aeroméxico” or the “Company”) today reported unaudited consolidated financial results for the three months ended March 31, 2026 (“1Q26”). These results are based on information available to us as of the date of this earnings release and are not a comprehensive statement of our financial results for the period presented. The Company has used the U.S. dollar, its functional currency, as the presentation currency for its consolidated financial statements. All figures are expressed in millions of U.S. dollars unless otherwise indicated....

Converse, Indiana, April 21, 2026 (GLOBE NEWSWIRE) -- Converse, Indiana (April 21, 2026) — Previous release issued with incorrect headline on Tuesday, April 21, 2026 by First Farmers Financial Corp., please note that the headline should be "First Farmers Financial Corp. Announces Two-for-One Stock Split", not "First Farmers Financial Corp. Declares Record Dividend". The corrected release follows: ...

BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycemia...

VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced results from the dose-escalation part of the Phase 1 study for ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the 2026 American Association for Cancer Research (AACR) Annual Meeting....

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- National Healthcare Properties, Inc. (“NHP”) today announced the pricing of its public offering of 38,500,000 shares of its Class A common stock at $12.00 per share. Shares of NHP's Class A common stock are expected to begin trading on The Nasdaq Global Market on April 22, 2026 under the symbol “NHP” and the offering is expected to close on April 23, 2026, subject to customary closing conditions. NHP has granted the underwriters a 30-day option to purchase up to an additional 5,775,000 shares of its Class A common stock to cover overallotments, if any....

Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer...

Equus Announces Q4 2025 Net Asset Value...